<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>ACR 2025 Vasculitis Resources | Alison Bays, MD</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: linear-gradient(135deg, #f5f0f0 0%, #fff5f5 100%);
            min-height: 100vh;
            color: #19375f;
        }

        .header {
            background: linear-gradient(135deg, #19375f 0%, #2d5a8c 100%);
            color: white;
            padding: 2rem;
            text-align: center;
        }

        .header h1 {
            font-size: 2.5rem;
            margin-bottom: 0.5rem;
        }

        .header p {
            opacity: 0.9;
            font-size: 1.1rem;
        }

        .author-info {
            margin-bottom: 1rem;
        }

        .author-info a {
            color: #ffd700;
            text-decoration: none;
            margin: 0 0.5rem;
        }

        .container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 2rem;
        }

        .section {
            background: white;
            border-radius: 12px;
            padding: 1.5rem;
            margin-bottom: 1.5rem;
            box-shadow: 0 2px 8px rgba(25, 55, 95, 0.1);
            border-left: 4px solid #19375f;
        }

        .section h2 {
            color: #19375f;
            margin-bottom: 1rem;
            font-size: 1.5rem;
        }

        .section h3 {
            color: #19375f;
            margin: 1rem 0 0.5rem 0;
            font-size: 1.1rem;
        }

        .trial-card {
            background: linear-gradient(135deg, #fff5f5 0%, #ffe4e9 100%);
            border-radius: 8px;
            padding: 1rem;
            margin-bottom: 0.75rem;
        }

        .trial-card h4 {
            color: #19375f;
            margin-bottom: 0.25rem;
            display: flex;
            align-items: center;
            gap: 0.5rem;
            flex-wrap: wrap;
        }

        .tag {
            font-size: 0.7rem;
            padding: 0.2rem 0.5rem;
            border-radius: 4px;
            font-weight: bold;
        }

        .tag-gca { background: #e3f2fd; color: #1565c0; }
        .tag-egpa { background: #fff3e0; color: #e65100; }
        .tag-aav { background: #e8f5e9; color: #2e7d32; }
        .tag-igg4 { background: #f3e5f5; color: #7b1fa2; }
        .tag-other { background: #fce4ec; color: #c2185b; }

        .trial-links {
            margin-top: 0.5rem;
            font-size: 0.9rem;
        }

        .trial-links a {
            color: #2d5a8c;
            text-decoration: none;
            margin-right: 1rem;
        }

        .trial-links a:hover {
            text-decoration: underline;
        }

        .abstract-item {
            background: #fffbf0;
            border-left: 3px solid #ffc107;
            padding: 0.5rem 0.75rem;
            margin-bottom: 0.5rem;
            border-radius: 0 4px 4px 0;
        }

        .abstract-item a {
            color: #19375f;
            text-decoration: none;
        }

        .abstract-item a:hover {
            text-decoration: underline;
        }

        .abstract-number {
            font-weight: bold;
            color: #c62828;
            margin-right: 0.5rem;
        }

        .news-section {
            background: linear-gradient(135deg, #e8f5e9 0%, #c8e6c9 100%);
            border-radius: 8px;
            padding: 1rem;
            margin-top: 1rem;
        }

        .news-section h4 {
            font-size: 1rem;
            color: #2e7d32;
            margin-bottom: 0.75rem;
            display: flex;
            align-items: center;
            gap: 0.5rem;
        }

        .news-section a {
            display: block;
            color: #1b5e20;
            text-decoration: none;
            font-size: 0.9rem;
            padding: 0.4rem 0;
            border-bottom: 1px solid rgba(0,0,0,0.1);
        }

        .news-section a:last-child {
            border-bottom: none;
        }

        .news-section a:hover {
            text-decoration: underline;
            color: #2e7d32;
        }

        .footer {
            background: #19375f;
            color: white;
            text-align: center;
            padding: 2rem;
            margin-top: 2rem;
        }

        .footer a {
            color: white;
            text-decoration: none;
            display: inline-block;
            margin: 0.5rem 1rem;
            padding: 0.5rem 1rem;
            border: 1px solid rgba(255,255,255,0.3);
            border-radius: 20px;
        }

        .footer a:hover {
            background: rgba(255,255,255,0.1);
        }

        .late-breaking {
            background: linear-gradient(135deg, #fff8e1 0%, #ffecb3 100%);
            border-left-color: #ffc107;
        }

        .publication-link {
            display: inline-block;
            background: #e3f2fd;
            color: #1565c0;
            padding: 0.2rem 0.5rem;
            border-radius: 4px;
            font-size: 0.8rem;
            margin-left: 0.5rem;
            text-decoration: none;
        }

        .publication-link:hover {
            background: #bbdefb;
        }

        @media (max-width: 768px) {
            .header h1 { font-size: 1.8rem; }
            .container { padding: 1rem; }
        }
    </style>
</head>
<body>
    <div class="header">
        <div class="author-info">
            <strong>Alison Bays, MD</strong><br>
            <a href="https://rheumify.org">üåê Rheumify.org</a> ‚Ä¢
            <a href="https://rheumify.substack.com">üì∞ Substack</a>
        </div>
        <h1>ü©∫ ACR Convergence 2025</h1>
        <p>Vasculitis Highlights & Resources</p>
        <p>Chicago, IL ‚Ä¢ November 14-19, 2025</p>
        <p style="margin-top: 1rem;"><a href="https://acrabstracts.org/meetings/acr-convergence-2025/" style="color: #ffd700; text-decoration: none; padding: 0.5rem 1rem; border: 1px solid #ffd700; border-radius: 20px;">üîç Search All ACR 2025 Abstracts</a></p>
    </div>

    <div class="container">
        <!-- Key Trials Section -->
        <div class="section">
            <h2>üîë Key Trials & Publications</h2>

            <div class="trial-card">
                <h4>SELECT-GCA 2-Year Extension <span class="tag tag-gca">GCA</span></h4>
                <div class="trial-links">
                    ‚Üí <a href="https://acrabstracts.org/abstract/efficacy-and-safety-of-upadacitinib-in-giant-cell-arteritis-2-year-results-from-the-re-randomized-double-blind-select-gca-phase-3-trial/">Abstract #0776</a>
                    <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2413449" class="publication-link">NEJM 2025</a>
                </div>
            </div>

            <div class="trial-card">
                <h4>METOGiA Trial <span class="tag tag-gca">GCA</span></h4>
                <div class="trial-links">
                    ‚Üí <a href="https://acrabstracts.org/abstract/methotrexate-versus-tocilizumab-for-treatment-of-giant-cell-arteritis-metogia-trial-a-multicenter-randomized-controlled-trial/">Abstract #0891</a>
                </div>
            </div>

            <div class="trial-card">
                <h4>MANDARA 2-Year Extension <span class="tag tag-egpa">EGPA</span></h4>
                <div class="trial-links">
                    ‚Üí <a href="https://acrabstracts.org/abstract/efficacy-of-anti-il-5-r-therapies-on-specific-disease-manifestations-of-eosinophilic-granulomatosis-with-polyangiitis/">Abstract #1608</a>
                    <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2311155" class="publication-link">NEJM 2024</a>
                </div>
            </div>

            <div class="trial-card">
                <h4>MITIGATE Subgroup Analysis <span class="tag tag-igg4">IgG4-RD</span></h4>
                <div class="trial-links">
                    ‚Üí <a href="https://acrabstracts.org/abstract/inebilizumab-efficacy-and-safety-in-patients-with-common-urgent-and-fibrotic-organ-manifestations-of-igg4-rd-subgroup-analyses-from-the-mitigate-trial/">Abstract #2020</a>
                    <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2409712" class="publication-link">NEJM 2024</a>
                </div>
            </div>
        </div>

        <!-- GCA Abstracts -->
        <div class="section">
            <h2>üî¨ Giant Cell Arteritis</h2>

            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/efficacy-and-safety-of-upadacitinib-in-giant-cell-arteritis-2-year-results-from-the-re-randomized-double-blind-select-gca-phase-3-trial/">
                    <span class="abstract-number">#0776</span> SELECT-GCA: 2-Year Extension Results (N=428)
                </a>
                <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2413449" class="publication-link">NEJM</a>
            </div>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/methotrexate-versus-tocilizumab-for-treatment-of-giant-cell-arteritis-metogia-trial-a-multicenter-randomized-controlled-trial/">
                    <span class="abstract-number">#0891</span> METOGiA: MTX vs TCZ for GCA (N=218)
                </a>
            </div>

            <div class="news-section">
                <h4>üì∞ In the News</h4>
                <a href="https://news.abbvie.com/2025-04-29-RINVOQ-R-upadacitinib-Receives-U-S-FDA-Approval-for-Giant-Cell-Arteritis-GCA">AbbVie: FDA Approves Rinvoq for GCA (Apr 2025)</a>
                <a href="https://www.the-rheumatologist.org/article/fda-approves-upadacitinib-for-gca/">The Rheumatologist: Upadacitinib Approval Coverage</a>
            </div>
        </div>

        <!-- EGPA Abstracts -->
        <div class="section">
            <h2>üî¨ Eosinophilic Granulomatosis with Polyangiitis (EGPA)</h2>

            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/efficacy-of-anti-il-5-r-therapies-on-specific-disease-manifestations-of-eosinophilic-granulomatosis-with-polyangiitis/">
                    <span class="abstract-number">#1608</span> MANDARA 2-Year: Efficacy on Disease Manifestations
                </a>
                <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2311155" class="publication-link">NEJM</a>
            </div>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/classification-of-relapses-of-eosinophilic-granulomatosis-with-polyangiitis-after-two-years-of-treatment-with-anti-interleukin-5-receptor-therapy/">
                    <span class="abstract-number">#1769</span> MANDARA 2-Year: Classification of Relapses
                </a>
            </div>

            <div class="news-section">
                <h4>üì∞ In the News</h4>
                <a href="https://www.astrazeneca.com/media-centre/medical-releases/mandara-phase-iii-data-published-new-england-journal-medicine-show-remission-achievable-goal-eosinophilic-granulomatosis-polyangiitis-egpa-fasenra.html">AstraZeneca: MANDARA NEJM Publication Announcement</a>
                <a href="https://www.pulmonologyadvisor.com/news/benralizumab-vs-mepolizumab-for-egpa/">Pulmonology Advisor: Benralizumab vs Mepolizumab for EGPA</a>
            </div>
        </div>

        <!-- AAV Abstracts -->
        <div class="section">
            <h2>üî¨ ANCA-Associated Vasculitis</h2>

            <h3>Avacopan Safety</h3>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/risk-of-drug-induced-liver-injury-with-use-of-avacopan-in-anca-vasculitis-results-from-real-world-data/">
                    <span class="abstract-number">#0724</span> Avacopan Liver Injury Risk: Real-World Data (N=29,163)
                </a>
            </div>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/a-disproportionality-analysis-of-fda-adverse-event-reporting-system-faers-events-for-avacopan/">
                    <span class="abstract-number">#2519</span> Avacopan FAERS Disproportionality Analysis
                </a>
            </div>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/reporting-of-infectious-and-hepatic-adverse-events-with-avacopan-insights-from-the-world-health-organization-pharmacovigilance-database-vigibase/">
                    <span class="abstract-number">#2507</span> Avacopan: WHO VigiBase Hepatic AE Analysis
                </a>
            </div>

            <h3>Outcomes & Prognostic Tools</h3>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/danger-score-as-predictor-of-mortality-in-anca-associated-vasculitis-with-or-without-glomerulonephritis-data-from-the-almenara-vasculitis-cohort/">
                    <span class="abstract-number">#2521</span> DANGER Score: Mortality Predictor in AAV
                </a>
            </div>

            <div class="news-section">
                <h4>üì∞ In the News</h4>
                <a href="https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr2.70001">ACR Open Rheumatology: Avacopan Combined Safety Data</a>
                <a href="https://academic.oup.com/rheumatology/article/64/5/2533/7923427">Rheumatology Journal: Drug-Induced Liver Injury with Avacopan</a>
            </div>
        </div>

        <!-- IgG4-RD Abstracts -->
        <div class="section">
            <h2>üî¨ IgG4-Related Disease</h2>

            <h3>MITIGATE Trial & Inebilizumab</h3>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/inebilizumab-efficacy-and-safety-in-patients-with-common-urgent-and-fibrotic-organ-manifestations-of-igg4-rd-subgroup-analyses-from-the-mitigate-trial/">
                    <span class="abstract-number">#2020</span> MITIGATE: Subgroup Analysis by Organ Manifestations
                </a>
                <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2409712" class="publication-link">NEJM</a>
            </div>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/clinical-and-biomarker-characteristics-of-inebilizumab-treated-participants-who-experienced-an-igg4-rd-flare-during-the-phase-3-mitigate-trial/">
                    <span class="abstract-number">#1163</span> MITIGATE: Biomarker Analysis of Flares
                </a>
            </div>

            <h3>Treatment & Management</h3>
            <div class="abstract-item late-breaking">
                <a href="https://acrabstracts.org/abstract/tofacitinib-plus-glucocorticoids-can-effectively-reduce-relapse-rate-in-igg4-related-disease-a-randomizedopen-label-controlled-trial/">
                    <span class="abstract-number">#LB02</span> ‚≠ê LATE-BREAKING: Tofacitinib + GC Reduces Relapse (RCT, N=58)
                </a>
            </div>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/safety-of-rilzabrutinib-a-btk-inhibitor-in-adult-patients-with-igg4-related-disease-igg4-rd-in-a-52-week-phase-2-open-label-study/">
                    <span class="abstract-number">#0239</span> Rilzabrutinib (BTK Inhibitor): Phase 2 Safety (N=27)
                </a>
            </div>

            <div class="news-section">
                <h4>üì∞ In the News</h4>
                <a href="https://www.amgen.com/newsroom/press-releases/2025/04/uplizna-inebilizumabcdon-is-now-the-first-and-only-fdaapproved-treatment-for-igg4related-disease">Amgen: FDA Approves Uplizna for IgG4-RD (Apr 2025)</a>
                <a href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-12-08-30-00-3098093">Sanofi: Rilzabrutinib EULAR 2025 Data</a>
                <a href="https://www.healio.com/news/rheumatology/20250403/rilzabrutinib-granted-orphan-drug-designation-for-igg4related-disease">Healio: Rilzabrutinib Orphan Drug Designation</a>
            </div>
        </div>

        <!-- Other Vasculitis -->
        <div class="section">
            <h2>üî¨ Other Vasculitis</h2>

            <h3>IgA Vasculitis</h3>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/cutaneous-iga-vasculitis-emulation-of-a-target-trial-from-a-european-multicentric-retrospective-study/">
                    <span class="abstract-number">#2699</span> Cutaneous IgA Vasculitis: Colchicine vs Dapsone vs GC (N=208)
                </a>
            </div>

            <h3>Large Vessel Vasculitis Guidelines</h3>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/a-systematic-literature-review-to-inform-the-2025-eular-recommendations-for-management-of-polymyalgia-rheumatica-and-large-vessel-vasculitis-management-of-disease-including-relapse-and-complications/">
                    <span class="abstract-number">#1627</span> 2025 EULAR PMR & LVV Recommendations: Systematic Review
                </a>
            </div>
        </div>
    </div>

    <div class="footer">
        <p>Compiled by <strong>Alison Bays, MD</strong></p>
        <p>ACR Convergence 2025 ‚Ä¢ Chicago, IL</p>
        <div>
            <a href="https://rheumify.org">üåê Rheumify.org</a>
            <a href="https://rheumify.substack.com">üì∞ Rheumify Substack</a>
        </div>
        <p style="margin-top: 1rem; font-size: 0.9rem; opacity: 0.8;">For educational purposes only. Always verify with primary sources.</p>
    </div>
</body>
</html>
